©The Author(s) 2026.
World J Gastrointest Oncol. Feb 15, 2026; 18(2): 115944
Published online Feb 15, 2026. doi: 10.4251/wjgo.v18.i2.115944
Published online Feb 15, 2026. doi: 10.4251/wjgo.v18.i2.115944
Table 3 Comparative clinical studies evaluating perioperative and oncologic outcomes of propofol vs sevoflurane in gastric cancer surgery
| Ref. | Key findings | Method |
| Wang et al[10] | No difference in long-term survival; propofol group had more PONV | Retrospective clinical |
| Zheng et al[18] | Fewer inflammatory complications and better postoperative recovery with propofol | Retrospective clinical |
| Wu et al[25] | Propofol group showed better long-term survival | Retrospective clinical |
| Oh et al[26] | One-year mortality lower with propofol | Retrospective analysis |
| Ai and Wang[19] | Propofol → Higher NK cell activity (immune advantage) | Prospective clinical |
| Song et al[28] | No significant difference in AKI incidence | Retrospective matched analysis |
| Li et al[27] | Propofol → Better cognitive and emotional postoperative recovery | Clinical study |
- Citation: Arun O, Arun F. Does anesthesia choice shape oncologic destiny in gastric cancer surgery? World J Gastrointest Oncol 2026; 18(2): 115944
- URL: https://www.wjgnet.com/1948-5204/full/v18/i2/115944.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v18.i2.115944